Prelude Therapeutics Inc Stock Price, News & Analysis

Prelude Therapeutics reported a strong cash position of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024. The company provided updates on its clinical pipeline, including the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527, all on track for significant milestones in 2H2022. Research and Development expenses rose to $22.8 million, while General and Administrative expenses increased to $7.5 million. The net loss for the quarter was $29.5 million, or $0.63 per share, reflecting higher operational costs.

Prelude Therapeutics (Nasdaq: PRLD) reported significant progress in 2021, expanding its pipeline to six internally discovered small molecule compounds targeting cancer pathways. The company aims to demonstrate proof-of-concept data for these compounds in 2022. With cash reserves of $291.2 million, Prelude anticipates funding operations into the second half of 2024. However, R&D expenses rose to $86.8 million, and net losses increased to $111.7 million, or $2.43 per share. Strategic prioritization includes focusing on lead candidate PRT811 in the PRMT5 program.

Prelude Therapeutics (Nasdaq: PRLD), a precision oncology company, announced that CEO Kris Vaddi, PhD, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in Miami, FL, on March 17, 2022, at 9:00 a.m. ET. A live webcast will be available on the company's website under the 'Investors' page. Prelude Therapeutics is focused on developing innovative drug candidates targeting critical cancer cell pathways, with a diverse pipeline including four clinical candidates and two preclinical ones aimed at addressing underserved cancer patients.

Prelude Therapeutics Inc. (Nasdaq: PRLD) has announced strategic advancements in its oncology pipeline, highlighting a focus on lead programs targeting PRMT5 and MCL1. The company introduced PRT3645, a brain penetrant CDK4/6 inhibitor, with an IND submission planned for mid-2022. Additionally, it aims to establish a recommended Phase 2 dose for PRT2527, a selective CDK9 inhibitor, by 2H/2022. Notably, Prelude is progressing a first-in-class SMARCA2/BRM degrader, with an IND submission expected by year-end 2022. Data from these programs will be showcased at the AACR Annual Meeting in April 2022.

Prelude Therapeutics (Nasdaq: PRLD) announced the appointment of Dr. Jane Huang as President and Chief Medical Officer, effective April 4, 2022. Dr. Huang brings extensive experience in oncology drug development, previously serving as Chief Medical Officer at BeiGene. CEO Kris Vaddi highlighted her strategic leadership as crucial for advancing Prelude’s precision oncology pipeline, which focuses on underserved cancers. Prelude is developing several promising drug candidates, including PRT543, PRT811, PRT1419, and PRT2527, targeting critical cancer cell pathways.

Prelude Therapeutics Inc. (NASDAQ: PRLD) announced that CEO Kris Vaddi, PhD, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. A live webcast can be accessed through the company's Investors page, with a replay available afterwards.

Prelude is a clinical-stage precision oncology company developing innovative treatments targeting critical cancer cell pathways. Their candidates include PRT543, PRT811, PRT1419, and PRT2527, focusing on various malignancies.

Prelude Therapeutics Inc. (Nasdaq: PRLD) announced that CEO Kris Vaddi, PhD, will present at the H.C Wainwright BioConnect Virtual Conference from January 10-13, 2022. The prerecorded presentation will be available on January 10, 2022, at 7:00 am ET on the company's Investors page. Prelude is a clinical-stage precision oncology company focusing on developing innovative cancer treatments, including PRMT5 inhibitors and MCL1 inhibitors in Phase 1 development. The company is advancing several pipelines aimed at targeting critical cancer cell pathways.

Prelude Therapeutics Inc. (Nasdaq: PRLD) announced that CEO Kris Vaddi, PhD, will speak at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 9:15 am ET. A live webcast and replay will be available on Prelude's 'Investors' page. The company focuses on developing precision oncology molecules targeting cancer pathways. Its candidates include PRT543 and PRT811 for solid tumors, CNS cancers, and myeloid malignancies, along with PRT1419 and PRT2527 for hematologic malignancies and solid tumors. Other promising projects are also in the pipeline.

Prelude Therapeutics (Nasdaq: PRLD) reported third-quarter 2021 financial results, revealing a net loss of $30.7 million, or $0.66 per share, compared to a $16.8 million loss in Q3 2020. The company holds a strong cash position of $320.9 million to support its clinical pipeline. Notable updates include favorable data from Phase 1 trials for PRMT5 inhibitors PRT543 and PRT811, which showed good tolerability and preliminary clinical activity. Additionally, PRT2527's IND was cleared by the FDA, with a Phase 1 trial anticipated by year-end.